Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis;Evaluación de la efectividad y la seguridad del natalizumab en el tratamiento de la esclerosis múltiple remitente recidivante

Farmacia Hospitalaria

Volumn 35, Issue 2, 2011, Pages 75-79

  Fernandez Megia M J ^a   Casanova, B ^a   Magraner, M J ^a   Font Noguera, I ^a   Poveda Andres J L ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Effectiveness; Natalizumab; Relapsing remitting multiple sclerosis; Safety

Indexed keywords

NATALIZUMAB; NEUTRALIZING ANTIBODY;

ADULT; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE; URTICARIA;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; BRAIN; FEMALE; HUMANS; INTEGRIN ALPHA4BETA1; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

EID: 79952738419     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farma.2010.02.003     Document Type: Article

References (11)

1. Ibarra O, Adévol M, Castillo I, Mora O, Ais A, Lovato E. Farmacoterapia ambulatoria: Farmacoterapia de la esclerosis múltiple. Curso de formación en farmacoterapia SEFH. Madrid: Aran; 2006.
2. García Merino JA, Blasco Quilez MR. Tratamiento farmacológico de la esclerosis múltiple. Inf Ter Sist Nac Salud. 2007;31:111-7.
3. Ficha técnica de Tysabri® [consultado 6/4/2009]. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/tysabri/H-603-PI-es.pdf.
4. National Institute for Health and Clinical Excellence NICE. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. Technology Appraisal Guidance N.o 127; 2007. Disponible en: www.nice.org.uk.
5. Polman C, O'Connor P, Havrdova E, Hutchinson M, Kappos L, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
6. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-23.
7. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390-401. (Pubitemid 46659091)
8. Alerta del 14 de agosto de 2008 de la Agencia Española del Medicamento y Productos Sanitarios [consultado 6/6/2009]. Disponible en: http://www.agemed.es/actividad/alertas/usoHumano/seguridad/home.htm.
9. Yousry TA, Habil M, Major EO, Ryschkewitsch C, Fahle G, Fischer S, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924-33.
10. Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR, et al. Quantifying the risk and benefits of natalizumab in relapsing multiple sclerosis. Neurology. 2007;68:1524-8. (Pubitemid 46685924)
11. Gold R, Jawad A, Millar DH, Henderson DC, Fassas A, Fierz W, et al. Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunology. 2007;187:156-8. (Pubitemid 47001540)